Show/Hide Menu
Hide/Show Apps
Logout
Türkçe
Türkçe
Search
Search
Login
Login
OpenMETU
OpenMETU
About
About
Open Science Policy
Open Science Policy
Open Access Guideline
Open Access Guideline
Postgraduate Thesis Guideline
Postgraduate Thesis Guideline
Communities & Collections
Communities & Collections
Help
Help
Frequently Asked Questions
Frequently Asked Questions
Guides
Guides
Thesis submission
Thesis submission
MS without thesis term project submission
MS without thesis term project submission
Publication submission with DOI
Publication submission with DOI
Publication submission
Publication submission
Supporting Information
Supporting Information
General Information
General Information
Copyright, Embargo and License
Copyright, Embargo and License
Contact us
Contact us
Advances in CRISPR/Cas9 Technology for in Vivo Translation
Download
index.pdf
Date
2019-03-01
Author
Cicek, Yagiz Anil
Luther, David C.
Kretzmann, Jessica A.
Rotello, Vincent M.
Metadata
Show full item record
This work is licensed under a
Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License
.
Item Usage Stats
197
views
0
downloads
Cite This
Clustered regularly interspaced short palindromic repeats(CRISPR)/CRISPR-associated protein 9 (Cas9) technology has revolutionized therapeutic gene editing by providing researchers with a new method to study and cure diseases previously considered untreatable. While the full range and power of CRISPR technology for therapeutics is being elucidated through in vitro studies, translation to in vivo studies is slow. To date there is no totally effective delivery strategy to carry CRISPR components to the target site in vivo. The complexity of in vivo delivery is furthered by the number of potential delivery methods, the different forms in which CRISPR can be delivered as a therapeutic, and the disease target and tissue type in question. There are major challenges and limitations to delivery strategies, and it is imperative that future directions are guided by well-conducted studies that consider the full effect these variables have on the eventual outcome. In this review we will discuss the advances of the latest in vivo CRISPR/Cas9 delivery strategies and highlight the challenges yet to be overcome.
Subject Keywords
Pharmacology
,
Pharmaceutical Science
,
General Medicine
URI
https://hdl.handle.net/11511/67829
Journal
BIOLOGICAL & PHARMACEUTICAL BULLETIN
DOI
https://doi.org/10.1248/bpb.b18-00811
Collections
Department of Chemistry, Article
Suggestions
OpenMETU
Core
Prospective evaluation of Vitamin K2, Raloxifene and their co-administration in osteoporotic rats
Tasci, A. G.; BİLGİLİ, HASAN; Altunay, H.; Gecit, M. R.; Keskin, Dilek (Elsevier BV, 2011-07-17)
In this study, therapeutic effects of Vitamin K2, Raloxifene and their co-administration on bone, uterus, blood and weight profiles were investigated with an ovariectomized rat model. Forty Wistar rats were divided into five groups (n = 8): Raloxifene (R), Vitamin K2 (K), Raloxifene + Vitamin K2 (R + K), ovariectomized controls (OVX) and Sham-operated controls (Sham). Treatment began 3 months after ovariectomy. Vitamin K2 and Raloxifene were administered 30 and 1.5 mg/kg/day separately and in combination fi...
CpG ODN Nanorings Induce IFN alpha from Plasmacytoid Dendritic Cells and Demonstrate Potent Vaccine Adjuvant Activity
Gungor, Bilgi; Yagci, Fuat Cem; Tincer, Gizem; Bayyurt, Banu; Alpdundar, Esin; Yildiz, Soner; Ozcan, Mine; GÜRSEL, İHSAN; Gürsel, Mayda (American Association for the Advancement of Science (AAAS), 2014-05-07)
CpG oligodeoxynucleotides (ODN) are short single-stranded synthetic DNA molecules that activate the immune system and have been found to be effective for preventing and treating infectious diseases, allergies, and cancers. Structurally distinct classes of synthetic ODN expressing CpG motifs differentially activate human immune cells. K-type ODN (K-ODN), which have progressed into human clinical trials as vaccine adjuvants and immunotherapeutic agents, are strong activators of B cells and trigger plasmacytoi...
Role of STRO-1 sorting of porcine dental germ stem cells in dental stem cell-mediated bone tissue engineering
Pekozer, Gorke Gurel; Ramazanoglu, Mustafa; Schlegel, Karl Andreas; Kök, Fatma Neşe; KÖSE, GAMZE (Informa UK Limited, 2018-01-01)
Stem cells of dental origin emerged as a new source for the regeneration of tissues with advantages mainly including non-invasive collection procedures and lack of ethical contraversies with their harvest or use. In this study, porcine TGSCs (pTGSCs) were isolated from mandibular third molar tooth germs of 6-month-old domestic pigs. This is the first study that reports the isolation and characterization of TGSCs from porcine third molars and their differentiation depending on STRO-1 expression. PTGSCs were ...
Using mathematical models to understand the effect of nanoscale roughness on protein adsorption for improving medical devices
Ercan, Batur; Carpenter, Joseph; Webster, Thomas J. (Informa UK Limited, 2013-01-01)
Surface roughness and energy significantly influence protein adsorption on to biomaterials, which, in turn, controls select cellular adhesion to determine the success and longevity of an implant. To understand these relationships at a fundamental level, a model was originally proposed by Khang et al to correlate nanoscale surface properties (specifically, nanoscale roughness and energy) to protein adsorption, which explained the greater cellular responses on nanostructured surfaces commonly reported in the ...
Doxorubicin loading, release, and stability of polyamidoamine dendrimer-coated magnetic nanoparticles
Rouhollah, Khodadust; Pelin, Mutlu; Serap, Yalcin; Gozde, Unsoy; Ufuk, Gunduz (Elsevier BV, 2013-06-01)
Nanotechnology is a promising alternative to overcome the limitations of classical chemotherapy. As a novel approach, dendrimer-coated magnetic nanoparticles (DcMNPs) maintain suitable drug delivery system because of their buildup of functional groups, symmetry perfection, nanosize, and internal cavities. They can also be targeted to the tumor site in a magnetic field. The aim of this study is to obtain an effective targeted delivery system for doxorubicin, using polyamidoamine (PAMAM) DcMNPs. Different gen...
Citation Formats
IEEE
ACM
APA
CHICAGO
MLA
BibTeX
Y. A. Cicek, D. C. Luther, J. A. Kretzmann, and V. M. Rotello, “Advances in CRISPR/Cas9 Technology for in Vivo Translation,”
BIOLOGICAL & PHARMACEUTICAL BULLETIN
, pp. 304–311, 2019, Accessed: 00, 2020. [Online]. Available: https://hdl.handle.net/11511/67829.